TY  - JOUR
AU  - Haugaard-Kedström, Linda M
AU  - Clemmensen, Louise S
AU  - Sereikaite, Vita
AU  - Jin, Zeyu
AU  - Fernandes, Eduardo F A
AU  - Wind, Bianca
AU  - Abalde-Gil, Flor
AU  - Daberger, Jan
AU  - Vistrup-Parry, Maria
AU  - Aguilar-Morante, Diana
AU  - Leblanc, Raphael
AU  - Egea-Jimenez, Antonio L
AU  - Albrigtsen, Marte
AU  - Jensen, Kamilla E
AU  - Jensen, Thomas M T
AU  - Ivarsson, Ylva
AU  - Vincentelli, Renaud
AU  - Hamerlik, Petra
AU  - Andersen, Jeanette Hammer
AU  - Zimmermann, Pascale
AU  - Lee, Weontae
AU  - Strømgaard, Kristian
PY  - 2021
DO  - 10.1021/acs.jmedchem.0c00382
UR  - https://hdl.handle.net/10668/26203
T2  - Journal of medicinal chemistry
AB  - Despite the recent advances in cancer therapeutics, highly aggressive cancer forms, such as glioblastoma (GBM), still have very low survival rates. The intracellular scaffold protein syntenin, comprising two postsynaptic density...
LA  - en
KW  - Animals
KW  - Antineoplastic Agents
KW  - Brain Neoplasms
KW  - Cell Line, Tumor
KW  - Drug Delivery Systems
KW  - Glioblastoma
KW  - High-Throughput Screening Assays
KW  - Humans
KW  - Ligands
KW  - Mice
KW  - Microsomes
KW  - Models, Molecular
KW  - Mutation
KW  - Peptides
KW  - Protein Binding
KW  - Syntenins
KW  - X-Ray Diffraction
KW  - Xenograft Model Antitumor Assays
TI  - A High-Affinity Peptide Ligand Targeting Syntenin Inhibits Glioblastoma.
TY  - research article
VL  - 64
ER  -